Oruka Therapeutics, Inc. ORKA Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -24.7%+42.9pp | -67.6%-54.0pp | -13.6%+7.8pp | -21.4%+18.2pp | |
| Return on invested capital | -32.6%— | —— | —— | —— | |
| Liquidity | |||||
| Current ratio | 22.4×-6.5× | 28.9×-30.1× | 59×+21.3× | 37.7×+22.2× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Valuation | |||||
| Market capitalization | $1.47B+116% | $678.62M— | —— | —— | |
| Price / book | 3.1×+1.3× | 1.8×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Oruka Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Oruka Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.